Pulmonx Corporation (Zephyr)

$80$125

“Pulmonx provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company’s solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013”

Report ID:

UMHE21977

Published:

Jan-2022

Pages:

14

Industry:

HeadQuatered Country:

United States

Geography:

Clear
  Get a Free Sample
SKU: UMHE21977 Category:
Scope
Table of content
Companies Mentioned

Scope

“Overview of the company and its product offering
Detailed insight into its Strategy, Vision, Product Portfolio, and Business Headquarter
Information on its recent developments including partnerships, collaborations, and expansions among others
Biography of top management”

You can also purchase parts of this report. Do you want to check out a section wise
price list?

“1. Key Facts of the Company
2. Company Mission
3. Company Value
4. Growth Strategy
5. Key Products & Services Offered
6. Infographic
7. Competitors
8. History/Timeline
9. Executive Team
10. SWOT Analysis
11. Company Revenue Split
12. Key Financials
13. Recent Development
13.1 Product Launches
13.2 Business Expansions & Investments “

Companies Mentioned

“Silk Road Medical Inc
Biosensors International Group
SpineWave